Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526450 | 0.87 | MYC (0.51) | TTRPTPRCNR1H4POLBKMT2A | |
| SCHEMBL2744380 | 0.82 | MYC (0.53) | S1PR4TTRPTPRCNR1H4GRIK1 | |
| SCHEMBL3201162 | 0.79 | NR1H4 (0.59) | TTRNR1H4TYMS | |
| SCHEMBL2951399 | 0.79 | NR1H4 (0.51) | TTRNR1H4ALDH1A1SRD5A2TSHR | |
| SCHEMBL30159253 | 0.79 | NR1H4 (0.51) | TTRNR1H4ALDH1A1SRD5A2TSHR | |
| SCHEMBL31156076 | 0.79 | SRD5A2 (0.44) | TTRPTPRCNR1H4POLBKMT2A | |
| SCHEMBL14252435 | 0.78 | GRIK1 (0.50) | TTRPTPRCGRIK1GRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL3852306 | 0.78 | NR1H4 (0.58) | TTRNR1H4TYMS | |
| SCHEMBL2744766 | 0.78 | PLA2G7 (0.63) | PLA2G7TTRPTPRCGRIK1GRIA1 | |
| SCHEMBL2745957 | 0.78 | TTR (0.50) | PLA2G7TTRPTPRCGRIK1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | claimed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | claimed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | claimed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | BUONAMICI SILVIA (US) | 2015-01-22 | — | — | US | disclosed |
| CN-104224791-A | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG | 2014-12-24 | — | — | CN | disclosed |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | DORSCH MARION (US) | 2014-07-17 | — | — | US | disclosed |
| US-8778927-B2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| WO-2010037715-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2010-04-08 | — | — | WO | disclosed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | MTOR, ULK1, HRAS | PLA2G7 2830/4885S1PR4 2244/4885TTR 4718/4885 |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | PLA2G7 3529/4885S1PR4 4187/4885TTR 3747/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | PLA2G7 2867/4885S1PR4 1466/4885TTR 4803/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | PLA2G7 1080/4885S1PR4 3718/4885TTR 4869/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | PLA2G7 1080/4885S1PR4 3718/4885TTR 4869/4885 |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | PLA2G7 796/4885S1PR4 1463/4885TTR 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.